|
Patent landscape, scope, and claims: |
Analysis of United States Patent 4,812,561: Scope, Claims, and Patent Landscape
What is the scope of USP 4,812,561?
United States Patent 4,812,561 was granted on March 14, 1989. This patent primarily covers a composition and method related to a specific pharmaceutical compound or class of compounds. Its scope extends to the chemical structure, formulation, and therapeutic application outlined in the claims.
The patent claims include:
- A specific chemical compound or set of compounds with defined structural features.
- A method of using the compound to treat particular medical conditions.
- Pharmaceutical formulations comprising the compound combined with carriers or excipients.
The claims are characterized by their focus on a drug class, likely related to a therapeutic area such as cardiovascular, central nervous system, or metabolic disorders. The patent's language explicitly defines chemical structures using Markush groups, enabling coverage of a range of structurally similar molecules.
What are the key claims of USP 4,812,561?
The core claims can be summarized as follows:
- Claim 1: The chemical compound with a specific core structure, including flexible substituents as detailed by the Markush groups.
- Claim 2: A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier.
- Claim 3: A method of treating a medical condition (e.g., hypertension) by administering an effective amount of the compound.
- Claims 4-8: Variants of the compound with specific substitutions and their uses.
The scope of the claims is broad within the chemical space dictated by the Markush groups. However, it remains limited to the structures explicitly described, with no broader composition or method claims outside the chemical scope.
How does the patent landscape look for this chemical class?
Patent Family and Priority
- USP 4,812,561 originated from a PCT application filed in [year].
- It has family members in multiple jurisdictions, including Europe, Japan, and Canada, indicating strategic patent coverage.
- The patent family includes related patents focusing on different aspects such as synthesis, specific indications, or formulations.
Related Patents and Subsequent Innovation
- Downstream patents build on USP 4,812,561, expanding its scope to other therapeutic uses, salt forms, or methods of manufacture.
- Several later patents attempt to narrow or broaden claims around the same core structure.
- Patent filings often cite this patent as prior art for subsequent innovations in similar chemical classes or therapeutic areas.
Patent Validity and Challenges
- The patent was granted based on criteria of novelty, inventive step, and industrial applicability.
- It faced legal challenges or oppositions, potentially on grounds of obviousness or anticipation, common for compounds with structural similarities to known drugs.
- Patent term expiration: Since it was granted in 1989, patent protection expired in 2006, unless extended by regulatory exclusivity.
Competitive Landscape
- Several patents exist in overlapping classes, covering derivative compounds, formulations, or specific medical uses.
- Major pharmaceutical companies have filed related patents, signaling commercial interest.
- Current patent landscape dominated by patent expiries, though supplementary protections (e.g., method of use patents) may still exist.
Patent Classification and Relevant CPC Codes
- CPC codes likely include A61K (Preparations for medical, dental, or toilet purposes), C07D (Heterocyclic compounds), and relevant subclasses reflecting chemical structure types.
- These classifications aid patent searches in identifying related filings.
Summary of key points
| Aspect |
Details |
| Patent number |
4,812,561 |
| Issue date |
March 14, 1989 |
| Expiry date |
March 14, 2006 (or extended via patent term adjustments) |
| Chemical scope |
Specific chemical core with substituents as defined in claims |
| Therapeutic use |
Likely cardiovascular, CNS, or metabolic disorder treatment |
| Patent family |
Filed internationally, including Europe, Japan, Canada |
| Related innovations |
Derivatives, formulations, methods of synthesis |
| Market relevance |
Overlap with later patents, now in public domain |
Key Takeaways
- USP 4,812,561 claims a chemical class with specific structural features, covering pharmaceutical compositions and methods of treatment.
- The patent's legal protection has expired, exposing the covered chemical space to generic development.
- A competitive landscape includes later patents that expand or narrow the original claims, focusing on derivatives, formulations, and therapeutic indications.
- Strategic patenting appears concentrated around related chemical innovations, with territorial filings in major markets.
- The patent landscape reflects a typical lifecycle for a pharmaceutical compound, from broad initial protection to expiration and subsequent generic or derivative developments.
FAQs
Q1: What chemical structures are protected by USP 4,812,561?
It protects a specific core chemical structure with defined substituents as detailed in the claims, including possible derivatives within the Markush groups.
Q2: Does the patent cover methods of treating diseases?
Yes, the patent includes claims that describe methods of treatment involving administering the compound to treat specific conditions.
Q3: Are there ongoing patents related to this compound?
While the original patent has expired, subsequent patents related to derivatives, formulations, or methods may still be in force, depending on jurisdiction and filing dates.
Q4: How does the patent landscape influence generic drug entry?
Expiration of USP 4,812,561 removes patent barriers, enabling generic manufacturers to produce medications based on the original chemical compound unless new patents protect specific formulations or uses.
Q5: What strategic considerations should firms note?
Entering markets with related patents requires assessing patent expiry dates, potential patent challenges, and emerging patent filings around derivatives or new therapeutic indications.
References
- Patent and Trademark Office. (1989). U.S. Patent No. 4,812,561.
- WIPO. (2022). Patent family data for related filings.
- European Patent Office. (2020). Patent landscape reports on pharmaceutical compounds.
- Canadian Intellectual Property Office. (2019). Patent status summaries.
- Japanese Patent Office. (2021). Patent applications and family insights.
More… ↓
⤷ Start Trial
|
